增强紫杉醇对结直肠癌化疗疗效的研究进展

陈炳辰; 于恩达; 陈炳辰; 于恩达

doi:10.12206/j.issn.1006-0111.202007031

[1]

蔡建, 王磊. 回眸2018: 聚焦结直肠癌研究领域[J]. 中华胃肠外科杂志, 2019, 22(1):9-16. doi: 10.3760/cma.j.issn.1671-0274.2019.01.002

[2]

BENSON A B, VENOOK A P, AL-HAWARY M M, et al. Rectal cancer, version 2.2018, nccn clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw,2018,16(7):874-901. doi: 10.6004/jnccn.2018.0061

[3]

VAN CUTSEM E, CERVANTES A, ADAM R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer[J]. Ann Oncol,2016,27(8):1386-1422. doi: 10.1093/annonc/mdw235

[4]

TEMRAZ S, MUKHERJI D, ALAMEDDINE R, et al. Methods of overcoming treatment resistance in colorectal cancer[J]. Crit Rev Oncol,2014,89(2):217-230. doi: 10.1016/j.critrevonc.2013.08.015

[5]

BHALLA K N. Microtubule-targeted anticancer agents and apoptosis[J]. Oncogene,2003,22(56):9075-9086. doi: 10.1038/sj.onc.1207233

[6]

AHMED A A, WANG X, LU Z, et al. Modulating microtubule stability enhances the cytotoxic response of cancer cells to paclitaxel[J]. Cancer Res,2011,71(17):5806-5817. doi: 10.1158/0008-5472.CAN-11-0025

[7]

GUPTA N, HATOUM H, DY G K. First line treatment of advanced non-small-cell lung cancer-specific focus on albumin bound paclitaxel[J]. Int J Nanomedicine,2014,9:209-221.

[8]

ORR G A, VERDIER-PINARD P, MCDAID H, et al. Mechanisms of Taxol resistance related to microtubules[J]. Oncogene,2003,22(47):7280-7295. doi: 10.1038/sj.onc.1206934

[9]

RAMANATHAN B, JAN K Y, CHEN C H, et al. Resistance to paclitaxel is proportional to cellular total antioxidant capacity[J]. Cancer Res,2005,65(18):8455-8460. doi: 10.1158/0008-5472.CAN-05-1162

[10]

JOSHI N, SHANMUGAM T, KAVIRATNA A, et al. Proapoptotic lipid nanovesicles: synergism with paclitaxel in human lung adenocarcinoma A549 cells[J]. J Control Release,2011,156(3):413-420. doi: 10.1016/j.jconrel.2011.07.025

[11]

SLEDGE G W, NEUBERG D, BERNARDO P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193)[J]. J Clin Oncol,2003,21(4):588-592. doi: 10.1200/JCO.2003.08.013

[12]

JOSHI N, SHANMUGAM T, DESHMUKH A, et al. Apoptotic cascade inspired lipid nanovesicles show synergism with encapsulated paclitaxel in chemoresistant colon carcinoma[J]. Nanomedicine (Lond),2014,9(12):1789-1805. doi: 10.2217/nnm.13.182

[13]

SUN H L, KLOK H A, ZHONG Z Y. Polymers from nature and for nature[J]. Biomacromolecules,2018,19(6):1697-1700. doi: 10.1021/acs.biomac.8b00830

[14]

PHAM D T, SAELIM N, TIYABOONCHAI W. Alpha mangostin loaded crosslinked silk fibroin-based nanoparticles for cancer chemotherapy[J]. Colloids Surfaces B: Biointerfaces,2019,181:705-713. doi: 10.1016/j.colsurfb.2019.06.011

[15]

PHAM D T, SAELIM N, TIYABOONCHAI W. Crosslinked fibroin nanoparticles using EDC or PEI for drug delivery: physicochemical properties, crystallinity and structure[J]. J Mater Sci,2018,53(20):14087-14103. doi: 10.1007/s10853-018-2635-3

[16]

PHAM D T, SAELIM N, TIYABOONCHAI W. Paclitaxel loaded EDC-crosslinked fibroin nanoparticles: a potential approach for colon cancer treatment[J]. Drug Deliv Transl Res,2020,10(2):413-424. doi: 10.1007/s13346-019-00682-7

[17]

BU H, HE X, ZHANG Z, et al. A TPGS-incorporating nanoemulsion of paclitaxel circumvents drug resistance in breast cancer[J]. Int J Pharm,2014,471(1-2):206-213. doi: 10.1016/j.ijpharm.2014.05.039

[18]

CHOUDHURY H, GORAIN B, KARMAKAR S, et al. Improvement of cellular uptake, in vitro antitumor activity and sustained release profile with increased bioavailability from a nanoemulsion platform[J]. Int J Pharm,2014,460(1-2):131-143. doi: 10.1016/j.ijpharm.2013.10.055

[19]

DESAI A, VYAS T, AMIJI M. Cytotoxicity and apoptosis enhancement in brain tumor cells upon coadministration of paclitaxel and ceramide in nanoemulsion formulations[J]. J Pharm Sci,2008,97(7):2745-2756. doi: 10.1002/jps.21182

[20]

ZOU H, LI L, GARCIA CARCEDO I, et al. Synergistic inhibition of colon cancer cell growth with nanoemulsion-loaded paclitaxel and PI₃K/mTOR dual inhibitor BEZ235 through apoptosis[J]. Int J Nanomedicine,2016,11:1947-1958. doi: 10.2217/nnm-2016-0147

[21]

KELLEHER R J III, SHEN J. Presenilin-1 mutations and Alzheimer's disease[J]. PNAS,2017,114(4):629-631. doi: 10.1073/pnas.1619574114

[22]

YONG Y L, ZHANG R Y, LIU Z K, et al. Gamma-secretase complex-dependent intramembrane proteolysis of CD147 regulates the Notch1 signaling pathway in hepatocellular carcinoma[J]. J Pathol,2019,249(2):255-267. doi: 10.1002/path.5316

[23]

VAN ES J H, VAN GIJN M E, RICCIO O, et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells[J]. Nature,2005,435(7044):959-963. doi: 10.1038/nature03659

[24]

AKIYOSHI T, NAKAMURA M, YANAI K, et al. Gamma-secretase inhibitors enhance taxane-induced mitotic arrest and apoptosis in colon cancer cells[J]. Gastroenterology,2008,134(1):131-144. doi: 10.1053/j.gastro.2007.10.008

[25]

LU Y, LI C S, DONG Q. Chinese herb related molecules of cancer-cell-apoptosis: a minireview of progress between Kanglaite injection and related genes[J]. J Exp Clin Cancer Res,2008,27(1):1-5. doi: 10.1186/1756-9966-27-1

[26]

WANG Y J, ZHANG C Z, ZHANG S W, et al. Kanglaite sensitizes colorectal cancer cells to Taxol via NF-κΒ inhibition and connexin 43 upregulation[J]. Sci Rep,2017,7:1280. doi: 10.1038/s41598-017-01480-2

[27]

BLAJ C, SCHMIDT E M, LAMPRECHT S, et al. Oncogenic effects of high MAPK activity in colorectal cancer mark progenitor cells and persist irrespective of RAS mutations[J]. Cancer Res,2017,77(7):1763-1774. doi: 10.1158/0008-5472.CAN-16-2821

[28]

FRIDAY B B, ADJEI A A. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy[J]. Clin Cancer Res,2008,14(2):342-346. doi: 10.1158/1078-0432.CCR-07-4790

[29]

KATAYAMA K, YOSHIOKA S, TSUKAHARA S, et al. Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein[J]. Mol Cancer Ther,2007,6(7):2092-2102. doi: 10.1158/1535-7163.MCT-07-0148

[30]

ENGELMAN J A. Targeting PI₃K signalling in cancer: opportunities, challenges and limitations[J]. Nat Rev Cancer,2009,9(8):550-562. doi: 10.1038/nrc2664

[31]

XU R, NAKANO K, IWASAKI H, et al. Dual blockade of phosphatidylinositol 3'-kinase and mitogen-activated protein kinase pathways overcomes paclitaxel-resistance in colorectal cancer[J]. Cancer Lett,2011,306(2):151-160. doi: 10.1016/j.canlet.2011.02.042

[32]

CHAPUIS N, TAMBURINI J, GREEN A S, et al. Dual inhibition of PI₃K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia[J]. Clin Cancer Res,2010,16(22):5424-5435. doi: 10.1158/1078-0432.CCR-10-1102

[33]

MANARA M C, NICOLETTI G, ZAMBELLI D, et al. NVP-BEZ235 as a new therapeutic option for sarcomas[J]. Clin Cancer Res,2010,16(2):530-540. doi: 10.1158/1078-0432.CCR-09-0816

[34]

ROPER J, RICHARDSON M P, WANG W V, et al. The dual PI₃K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer[J]. PLoS One,2011,6(9):e25132. doi: 10.1371/journal.pone.0025132